Article
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
PloS one - 2 Oct 2009
Sartore-Bianchi Andrea, Di Nicolantonio Federica, Nichelatti Michele, Molinari Francesca, De Dosso Sara, Saletti Piercarlo, Martini Miriam, Cipani Tiziana, Marrapese Giovanna, Mazzucchelli Luca, Lamba Simona, Veronese Silvio, Frattini Milo, Bardelli Alberto, Siena Salvatore
Abstract excerpt
BACKGROUND: KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.